ClinicalTrials.gg
CompletedNCT01374178Updated Oct 7, 2014Results posted

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

A Phase 1 interventional study of LY2963016 and Lantus in Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 81 studies testing Insulin Glargine in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus.

Enrollment
72nd of 81
16 · median 80
Started
2011
with 10 others
Phase 1
13 of 81
none open now
Registered
55th of 81
by date
Lead sponsor
7 of 81
Eli Lilly and Company

Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, this one is the 72nd largest by enrollment, is one of 11 that started in 2011, is one of 13 in phase 1, and was the 55th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 81 studies testing Insulin Glargine in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing Insulin Glargine in Diabetes Mellitus, or all of them as a file.
02

Study summary

The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy subjects. The study is approximately 12 weeks.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females
  • Have a (BMI) between 18.5 and 29.9 kilogram per square meter (kg/m\^2)
  • Are nonsmokers
  • Have normal blood pressure and pulse rate
  • Have an (ECG) considered as within normal limits
  • Have clinical laboratory test results within normal reference range

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an drug or device
  • Have known allergies to insulin or its
  • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
  • Show evidence of significant active neuropsychiatric disease
  • Have a history of first-degree relatives known to have diabetes mellitus
  • Have a fasting venous blood glucose >6.0 millimoles per liter (mmol/L)
  • Intend to use over-the-counter or prescription medication
  • Have donated or had a blood loss of 450 milliliters (mL) or more in the past 3 months
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    LY2963016

    A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.

    Drug: LY2963016

  • Active comparator
    Lantus

    A single 0.5-U/kg dose of Lantus will be administered subcutaneously.

    Drug: Lantus

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Concentration-Time Curve (AUC)

    AUC from time zero to 24 hours (AUC0-24) is reported for this outcome measure.

    Time frame: Periods 1 and 2: Baseline up to 24 hours

Secondary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax)

    Time frame: Periods 1 and 2: Baseline up to 24 hours

  2. Maximum Glucose Infusion Rate (Rmax)

    Time frame: Periods 1 and 2: Baseline up to 24 hours

  3. Total Glucose Infused (Gtot)

    Time frame: Periods 1 and 2: Baseline up to 24 hours

  4. Time of Maximum Glucose Infusion Rate (tRmax)

    Time frame: Periods 1 and 2: Baseline up to 24 hours

  5. Number of Participants With Clinically Significant Effects

    Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module.

    Time frame: Baseline up to 30 days

07

Results

Posted Oct 7, 2014

Participant flow

Period 1 (up to 24 Hours After Dosing)
Participant flow — Period 1 (up to 24 Hours After Dosing)
MilestoneLY2963016 First, Then LantusLantus First, Then LY2963016
Started115
Received at least 1 dose of ly2963016115
Completed115
Not completed00
Washout Period of at Least 7 Days
Participant flow — Washout Period of at Least 7 Days
MilestoneLY2963016 First, Then LantusLantus First, Then LY2963016
Started115
Completed105
Not completed10
Withdrew: Withdrawal by subject10
Period 2 (up to 24 Hours After Dosing)
Participant flow — Period 2 (up to 24 Hours After Dosing)
MilestoneLY2963016 First, Then LantusLantus First, Then LY2963016
Started105
Completed85
Not completed20
Withdrew: Adverse event20

Outcome measures

PrimaryPharmacokinetics: Area Under the Concentration-Time Curve (AUC)

AUC from time zero to 24 hours (AUC0-24) is reported for this outcome measure.

Time frame:
Periods 1 and 2: Baseline up to 24 hours
Reported as:
Geometric mean · picomole*hour per liter (pmol*hr/L)
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC)
picomole*hour per liter (pmol*hr/L)LY2963016Lantus
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC)1900 ± 222180 ± 30
SecondaryPharmacokinetics: Maximum Concentration (Cmax)
Time frame:
Periods 1 and 2: Baseline up to 24 hours
Reported as:
Geometric mean · picomole per liter (pmol/L)
Pharmacokinetics: Maximum Concentration (Cmax)
picomole per liter (pmol/L)LY2963016Lantus
Pharmacokinetics: Maximum Concentration (Cmax)110 ± 26130 ± 35
SecondaryMaximum Glucose Infusion Rate (Rmax)
Time frame:
Periods 1 and 2: Baseline up to 24 hours
Reported as:
Geometric mean · grams per hour (g/h)
Maximum Glucose Infusion Rate (Rmax)
grams per hour (g/h)LY2963016Lantus
Maximum Glucose Infusion Rate (Rmax)10.2 ± 5011.3 ± 32
SecondaryTotal Glucose Infused (Gtot)
Time frame:
Periods 1 and 2: Baseline up to 24 hours
Reported as:
Geometric mean · gram (g)
Total Glucose Infused (Gtot)
gram (g)LY2963016Lantus
Total Glucose Infused (Gtot)141 ± 54160 ± 36
SecondaryTime of Maximum Glucose Infusion Rate (tRmax)
Time frame:
Periods 1 and 2: Baseline up to 24 hours
Reported as:
Median · hour (h)
Time of Maximum Glucose Infusion Rate (tRmax)
hour (h)LY2963016Lantus
Time of Maximum Glucose Infusion Rate (tRmax)10.5 (5.40 to 15.1)10.2 (5.50 to 15.8)
SecondaryNumber of Participants With Clinically Significant Effects

Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module.

Time frame:
Baseline up to 30 days
Reported as:
Number · participants
Number of Participants With Clinically Significant Effects
participantsLY2963016Lantus
Serious Adverse Events00
Nonserious Adverse Events86

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2963016—0/16 (0%)8/16 (50%)
Lantus—0/13 (0%)6/13 (46.2%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventLY2963016Lantus
Catheter site swellingGeneral disorders3/161/13
DizzinessNervous system disorders2/160/13
Dry mouthGastrointestinal disorders0/161/13
VomitingGastrointestinal disorders0/161/13
Catheter site painGeneral disorders1/161/13
Pain in extremityMusculoskeletal and connective tissue disorders0/161/13
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/161/13
RashSkin and subcutaneous tissue disorders0/161/13
PalpitationsCardiac disorders1/160/13
NauseaGastrointestinal disorders1/160/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean31.1 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female3
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Entire Study Population
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Entire Study Population
American Indian or Alaska Native0
Asian14
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
Singapore16
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Singapore, Singapore
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2011
First posted
Jun 15, 2011
Start
Jun 2011
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01374178
Responsible party
Sponsor
First posted
Jun 15, 2011
Start date
Jun 2011
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion